Company Profile
Covance
Company Overview
Covance by Labcorp is a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries.
Our mission is to improve health and improve lives.
Our vision is to be recognized by clients as:
The undisputed leader in providing drug development services
A trusted partner whose hallmarks are
Great people
High-quality data
A proven track record of integrating and streamlining the development process
Our Values
Our values are to strive for operational and service excellence through a relentless focus on People, Process and Clients.
Company History
2015 LabCorp® (NYSE: LH) acquires Covance Inc., creating the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end solutions for drug and diagnostics development and commercialization.
2011 Takeda Pharmaceuticals International, Inc. chooses Covance as one of its strategic partners to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology.
2010 Covance signs landmark agreement with Sanofi-Aventis for a 10-year strategic R&D alliance and acquires their Porcheville, France and Alnwick, United Kingdom sites.
2009 Covance acquires Merck's Seattle-based Gene Expression Laboratory. Under the agreement, Merck has committed to a five-year $145 million contract to purchase genomic analysis services from Covance. Covance acquires Swiss Pharma Contract, a clinical research company based in Basel, Switzerland.
2008 Covance purchases minority equity stake in Caprion Proteomics, the leading provider of proteomics-based services to the pharmaceutical industry, to further enhance its biomarkers service offering to clients. Covance makes CRO history with the most comprehensive drug development partnership in the industry. Covance acquires Lilly’s Greenfield, Indiana campus and executes a 10-year service agreement with Lilly.
2007 In celebration of their 10-year anniversary, Covance announces our partnership with CARE to support the Covance-CARE Early Childhood Development (ECD) Initiative for Orphans and Vulnerable Children in Rwanda. Covance opens Central Labs facility in Shanghai, China.
2006 Covance announces acquisition of eight early phase clinical pharmacology sites of Radiant Research, Inc. Opens the largest toxicology expansion in Madison, Wisconsin.
2002 Covance acquires Virtual Central Labs, now known as Local Laboratory Services.
2000 Central STET laboratory opens in Singapore to serve fast-growing East Asian market. Covance expands pharmaceutical analysis facility in Harrogate, U.K. and Phase I clinical research unit in Leeds, U.K.
1998 Covance acquires the Berkeley (California) Antibody Company.
1997 Covance begins operations as an independent, publicly traded company on the New York Stock Exchange (NYSE) after our official spin-off from Corning Incorporated.